LDTs: FDA Approves First NGS Residual Cancer Detection Test
From - National Intelligence Report
The FDA broke new ground by allowing marketing of Adaptive Biotechnologies' ClonoSEQ assay, a next generation sequencing (NGS)-based test for…
From - National Intelligence Report
The FDA broke new ground by allowing marketing of Adaptive Biotechnologies' ClonoSEQ assay, a next generation sequencing (NGS)-based test for…
From - Diagnostic Testing & Emerging Technologies
In what has been called the "era of the medical selfie," at-home, smartphone-based urine testing is now a reality. In a short timeframe, the…
...
...
From - Laboratory Industry Report
How do you plan for the future in a rapidly changing environment? That is the big task that laboratories are being asked to do. There is no roadmap, yet their financial livelihood is dependent upon…